Geode Capital Management LLC Raises Holdings in Cognition Therapeutics, Inc. (NASDAQ:CGTX)

Geode Capital Management LLC lifted its stake in Cognition Therapeutics, Inc. (NASDAQ:CGTX) by 8.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 352,348 shares of the company’s stock after purchasing an additional 28,705 shares during the quarter. Geode Capital Management LLC owned about 0.85% of Cognition Therapeutics worth $247,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in shares of Cognition Therapeutics in the third quarter worth $27,000. SG Americas Securities LLC acquired a new position in shares of Cognition Therapeutics in the 4th quarter valued at $26,000. Sigma Planning Corp raised its stake in Cognition Therapeutics by 211.6% in the 4th quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock worth $431,000 after acquiring an additional 417,300 shares during the last quarter. Finally, BIOS Capital Management LP acquired a new stake in Cognition Therapeutics during the 4th quarter worth about $4,208,000. 43.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Chardan Capital cut their price objective on Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 21st. Brookline Capital Management upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. Finally, HC Wainwright decreased their price objective on shares of Cognition Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, March 24th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $7.13.

Cognition Therapeutics Stock Down 0.3 %

Shares of CGTX stock opened at $0.45 on Friday. The stock has a market cap of $27.63 million, a PE ratio of -0.46 and a beta of 1.01. Cognition Therapeutics, Inc. has a 52-week low of $0.31 and a 52-week high of $2.95. The business has a 50-day simple moving average of $0.41 and a 200-day simple moving average of $0.52.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same quarter in the prior year, the business earned ($0.27) earnings per share. Sell-side analysts anticipate that Cognition Therapeutics, Inc. will post -0.8 earnings per share for the current fiscal year.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.